ADG153, an Anti-CD47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass

Bin Cai, Jiangchun Xu(Pfizer (United States)), Yan Li(Beijing Tongren Hospital), Songmao Zheng, Guizhong Liu(Tianjin Hospital), Aaron Nguyen, Felix Du, Jianfeng Shi, Peter Luo
Blood
November 5, 2021
Cited by 4


Related Papers